Full-Time
Posted on 9/11/2026
Clinical-stage oncology company develops targeted therapies
$186k - $259k/yr
San Diego, CA, USA
In Person
Bachelor's
See people who can refer or advise you
Kura Oncology develops precision medicines for cancer, focusing on small-molecule drugs that target tumors with specific genetic mutations. It is in the clinical-stage, researching and developing its own drug candidates to eventually bring them to market. Its leading candidate, ziftomenib, blocks the menin-KMT2A/MLL protein interaction, offering a targeted approach for genetically defined acute myeloid leukemia (AML). The company is also pursuing tipifarnib for head and neck squamous cell carcinoma (HNSCC) and other solid tumors. By collaborating with academic institutions and other biotech companies, Kura Oncology expands its pipeline and advances therapies through clinical trials. The goal is to deliver effective, targeted cancer treatments for patients with unmet medical needs and to grow its portfolio through research, development, and partnerships.
Company Size
201-500
Company Stage
IPO
Headquarters
San Diego, California
Founded
2014
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Holidays
Paid Paternity/Maternity Leave
Home Office Stipend
Lifestyle Spending Stipend
Commuter Stipend
Wellness Program
Gym Membership
Company Social Events
Kura Oncology shares surged on 25 August after CEO Troy Wilson purchased 100,000 shares for approximately $1.24 million, following a $1.11 million investment days earlier. The stock has risen more than 50% from recent lows. Wilson's One Fish Two Fish Revocable Trust now holds 479,194 shares. The purchases signal confidence as the company's share price advances, though insider buying doesn't guarantee future gains. The rally follows the commercial launch of KOMZIFTI, an FDA-approved treatment for certain acute myeloid leukaemia patients. The drug generated $9.1 million in net revenue last quarter, up 57% sequentially, with new patient starts growing 35% to about 115. Kura Oncology expects $180 million in additional collaboration payments from Kyowa Kirin.
Troy Edward Wilson, CEO of Kura Oncology, purchased approximately 100,000 shares of the company's common stock for $1.2 million on 24 August 2026, according to an SEC Form 4 filing. The shares were acquired at $12.39 each. The transaction increased Wilson's total stock position by 9%, bringing his combined direct and indirect holdings to approximately 1.2 million shares valued at $15.06 million. Following the purchase, Wilson holds roughly 435,000 shares directly and 779,000 shares indirectly through the One Fish Two Fish Revocable Trust and the Lorax Charitable Remainder Unitrust. Kura Oncology, a clinical-stage biopharmaceutical company based in San Diego, has a market capitalisation of $1.1 billion. The company reported trailing twelve-month revenue of $77.2 million and a net loss of $296.8 million.
Kura Oncology's stock rose 14.5% following second-quarter results and publication of preclinical data on its FDA-approved menin inhibitor ziftomenib in the journal Blood. Revenue increased to $20.87 million, though net loss widened to $68.33 million. The Blood study showed ziftomenib retained activity against certain resistance-linked MEN1 mutations in leukaemia models, strengthening scientific confidence in the therapy. The drug is marketed as KOMZIFTI for relapsed or refractory NPM1-mutated AML and is being investigated for broader oncology applications. Despite the positive data, Kura remains unprofitable with substantial quarterly losses. Analyst revenue projections for 2029 range widely, from consensus estimates around $353 million to more optimistic forecasts of $861.5 million, reflecting uncertainty about the company's commercial trajectory.
Kura Oncology reported $9.1 million in net product revenue for COMZIFTI in Q2 2026, exceeding internal expectations. The company captured majority share of new patient starts in the relapsed/refractory NPM1-mutant AML menin inhibitor market within its second full commercial quarter, despite being second to market. Management attributes the rapid adoption to the product's differentiated profile, including predictable safety and dosing convenience. Physician-initiated combination use accounted for approximately 40% of new patient starts. The company has achieved over 90% engagement with top-priority AML accounts and secured market access covering over 95% of lives. Kura maintained collaboration revenue guidance of $45 million to $55 million for 2026. The pivotal KOMET-017 Phase 3 trial remains on track for top-line results in 2028.
Kura Oncology reported second quarter 2026 financial results, with KOMZIFTI generating $9.1 million in net product revenue, up 57% from the first quarter. The drug also achieved approximately 115 new patient starts, a 35% increase over the previous quarter. KOMZIFTI secured majority share of new patient starts in the relapsed or refractory NPM1-mutant AML menin inhibitor class after two full quarters on the market. The company reported more than 250 total prescriptions in the second quarter, up 59% from the first quarter. Research and development expenses totalled $61.9 million, whilst selling, general and administrative expenses reached $31.8 million. Net loss for the quarter was $68.3 million. As of 30 June 2026, Kura held $519.0 million in cash, cash equivalents and short-term investments, plus $180 million in anticipated collaboration payments from Kyowa Kirin.